Skip to main content
. 2022 Aug 9;13:955648. doi: 10.3389/fphar.2022.955648

FIGURE 12.

FIGURE 12

Strategies for the further structural optimization of arbidol (A), dolutegravir and bictegravir (B) and the structures of BD-2, Ti-2 and Ar-3.